Intec Pharma Reports Financial Results For The First Six Months Of 2017
JERUSALEM, Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, today reported financial results for the six months ended June 30, 2017.
Highlights of the first half of 2017 and recent weeks include:
Highlights of the first half of 2017 and recent weeks include: